Dabrafenib
Overview
Dabrafenib is a medication used in the treatment of certain types of cancer, specifically BRAF V600E mutation-positive unresectable or metastatic melanoma. It works by inhibiting the activity of BRAF, a kinase that is mutated in some cancer cells.
API suppliers (1)
Suppliers of Dabrafenib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
1 of 1 holds a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Dabrafenib expires 29 Dec 2038 and exclusivity 16 Sept 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Dabrafenib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.